Human endogenous retroviruses (HERVs) are remnants of ancient retroviral infections that
have become fixed in the human genome. While HERV genes are typically silenced in …

Human endogenous retroviruses (HERVs) comprise a significant portion of the human
genome, making up roughly 8%, a notable comparison to the 2–3% represented by coding …

Human endogenous retroviruses (HERVs) comprise about 8.3% of the human genome and
are capable of producing RNA molecules that can be sensed by pattern recognition …

The most active human endogenous retrovirus K (HERV-K) subtype, HML-2, has been
implicated as a driver of oncogenesis in several cancers. However, the presence and …

Background Gallbladder cancer (GBC), the most common malignancy of the biliary tract,
shows late diagnosis and low survival rate and requires continued search for new diagnostic …

Abstract TP53 mutation (TP53 mut) occurs in 10–20% of diffuse large B-cell lymphoma
(DLBCL) cases and serves as an unfavorable biomarker of DLBCL progression. It confers …

Background The “missing” link of complex and multifaceted interplay among endogenous
retroviruses (ERVs) transcription, chronic immuno-inflammation, and the development of …

In situ cancer vaccination refers to any approach that exploits tumour antigens available at a
tumour site to induce tumour-specific adaptive immune responses. These approaches hold …

While immune checkpoint blockade results in durable responses for some patients, many
others have not experienced such benefits. These treatments rely upon reinvigorating …

Simple Summary Human endogenous retrovirus (HERV) plays important roles in the
development of cancer, and most studies use data from The Cancer Genome Atlas to …